PD-1 Inhibitor or PD-1 Inhibitor Plus GVD for Relapsed/Refractory CHL
This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction therapy.
Classical Hodgkin Lymphoma|Refractory or Relapsed Classical Hodgkin Lymphoma
DRUG: PD-1 inhibitor|DRUG: PD-1 inhibitor, gemcitabine, vinorelbine and doxorubicin liposome
Complete remission rate, Complete remission rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria., 2 years
Objective Response rate, Objective Response rate will be determined on the basis of investigator assessments according to 2014 Lugano criteria., 2 years|Progression Free Survival, The time from the start of treatment to the progression of the tumor or death (due to any cause)., 5 years|Overall Survival, The time from the start of treatment to time of death (due to any cause)., 5 years|Duration of Response, The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause)., 5 years|Time to Response (TTR), The time from the start of treatment to the first assessment of complete remission or partial remission., 2 years|Percentage of Participants With Adverse Events, Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0, 2 years
This phase 2 trial studies the efficacy and safety of PD-1 inhibitor monotherapy or PD-1 inhibitor with GVD (Gemcitabine, Vinorelbine and Doxorubicin Liposome) regimen for relapsed or refractory classical Hodgkin lymphoma (CHL) patients who failed the first-line induction therapy.